1.Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The age-related eye disease study 2 (AREDS2) randomized clinical trial.JAMA 309(19):2005-2015, 2013.doi: 10.1001/jama.2013.4997.Clarification and additional information.JAMA 310(2):208, 2013.doi:10.1001/jama.2013.6403
2.Hogg RE, Woodside JV, McGrath A, et al: Mediterranean diet score and its association with age-related macular degeneration: The European Eye Study.Ophthalmology 124(1):82-89, 2017.doi: 10.1016/j.ophtha.2016.09.019
3.Christen WG, Cook NR, Manson JE, et al: Effect of vitamin D and ω-3 fatty acid supplementation on risk of age-related macular degeneration: An ancillary study of the VITAL randomized clinical trial.JAMA Ophthalmol 138(12):1280-1289, 2020.doi: 10.1001/jamaophthalmol.2020.4409
4.Heier JS, Lad EM, Holz FG, et al: Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.Lancet 402(10411):1434-1448, 2023.doi: 10.1016/S0140-6736(23)01520-9
5.Khanani AM, Patel SS, Staurenghi G, et al: Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.Lancet 402(10411):1449-1458, 2023. doi: 10.1016/S0140-6736(23)01583-0
6.Finger RP, Puth MT, Schmid M, Barthelmes D, et al: Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration.JAMA Ophthalmol 138(12):1234-1240, 2020.doi: 10.1001/jamaophthalmol.2020.3989
7.Wykoff CC, Brown DM, Reed K, et al.Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: The phase 2 CANDELA randomized clinical trial.JAMA Ophthalmol 141(9):834–842, 2023.doi: 10.1001/jamaophthalmol.2023.2421
8.Heier JS, Khanani AM, Quezada Ruiz C, et al: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.Lancet 399(10326):729-740, 2022.doi: 10.1016/S0140-6736(22)00010-1
9.Holekamp NM, Campochiaro PA, Chang MA, all Archway Investigators: Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration.Ophthalmology S0161-6420(21)00734-X, 2021
10.Dugel PU, Koh A, Ogura Y, HAWK and HARRIER Study Investigators: HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.Ophthalmology 127(1):72-84, 2020.doi: 10.1016/j.ophtha.2019.04.017
11.Haug SJ, Hien DL, Uludag G, et al: Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.Am J Ophthalmol Case Rep 18:100680, 2020.doi: 10.1016/j.ajoc.2020.100680